Lineage Cell Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 10, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 10, 2025
LCTX$1.08+5.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(IN THOUSANDS, EXCEPT PER SHARE DATA)
| Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| REVENUES: | ||
| Collaboration revenues | $8,149 | $7,588 |
| Royalties, license and other revenues | 1,350 | 1,357 |
| Total revenues | 9,499 | 8,945 |
| OPERATING EXPENSES: | ||
| Cost of sales | 334 | 671 |
| Research and development | 12,472 | 15,705 |
| General and administrative | 18,171 | 17,302 |
| Total operating expenses | 30,977 | 33,678 |
| Loss from operations | (21,478) | (24,733) |
| OTHER INCOME (EXPENSES): | ||
| Interest income, net | 1,715 | 1,629 |
| Loss on marketable equity securities, net | (8) | (176) |
| Change in fair value of warrant liability | 2,128 | — |
| Foreign currency transaction loss, net | (269) | (544) |
| Other income (expense), net | (670) | 542 |
| Total other income (expenses) | 2,896 | 1,451 |
| LOSS BEFORE INCOME TAXES | (18,582) | (23,282) |
| Provision for income tax benefit | — | 1,803 |
| NET LOSS | (18,582) | (21,479) |
| Net (income) loss attributable to noncontrolling interest | (27) | (7) |
| NET LOSS ATTRIBUTABLE TO LINEAGE | $(18,609) | $(21,486) |
| Net loss per common share attributable to Lineage basic and diluted | $(0.09) | $(0.12) |
| Weighted-average common shares used to compute basic and diluted net loss per common share | 200,193 | 172,663 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.